Active surveillance of patients with low and intermediate risk prostate cancer
- Authors: Andreeva R.D.1, Nizamova R.S.1, Vozdvizhenskii M.O.1,2, Zhurkina O.V.1, Isargapov R.M.2
-
Affiliations:
- Samara State Medical University
- Samara Regional Clinical Oncology Dispensary
- Issue: Vol 8, No 3 (2023)
- Pages: 198-204
- Section: Oncology and radiotherapy
- URL: https://journal-vniispk.ru/2500-1388/article/view/249949
- DOI: https://doi.org/10.35693/2500-1388-2023-8-3-198-204
- ID: 249949
Cite item
Full Text
Abstract
Aim – to analyze the survival of patients with localized low and intermediate risk prostate cancer receiving various types of treatment and active surveillance in the Samara region.
Material and methods. The study included 1474 patients with newly diagnosed localized prostate cancer in the Samara region for the period 2010-2016.
Results. In the Samara region, the radical prostatectomy proved to be the most effective treatment method. At the same time, the active surveillance was comparable to other treatment methods in men older than 75 years.
Conclusion. The active surveillance can improve the managing of prostate cancer patients by reducing overtreatment of its clinically insignificant forms, reducing treatment costs and reducing the number of side effects of radical treatment. At the same time, the possibility of radical treatment remains in case of malignant neoplasm progression.
Full Text
##article.viewOnOriginalSite##About the authors
Ramilya D. Andreeva
Samara State Medical University
Email: r.d.andreeva@samsmu.ru
ORCID iD: 0000-0001-5385-7049
assistant of the Department of Urology
Russian Federation, SamaraRumiya S. Nizamova
Samara State Medical University
Author for correspondence.
Email: r.s.nizamova@samsmu.ru
ORCID iD: 0000-0003-4452-8547
PhD, Professor, Head of the Department of Urology
Russian Federation, SamaraMikhail O. Vozdvizhenskii
Samara State Medical University; Samara Regional Clinical Oncology Dispensary
Email: VozdvijenskiyMO@samaraonko.ru
ORCID iD: 0000-0001-5851-0968
PhD, Professor, Department of Oncology; Deputy Chief physician for medical work
Russian Federation, Samara; SamaraOlga V. Zhurkina
Samara State Medical University
Email: o.v.zhurkina@samsmu.ru
ORCID iD: 0000-0002-6440-793X
PhD, Associate professor of the Department of Urology
Russian Federation, SamaraRuslan M. Isargapov
Samara Regional Clinical Oncology Dispensary
Email: Ruslan.isargapov@yandex.ru
urologist
Russian Federation, SamaraReferences
- Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492
- Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low-risk prostate cancer: risk assessment and treatment. J Urol. 2007;178(3Pt2):14-19. doi: 10.1016/j.juro.2007.03.135
- Veliev EI, Petrov SB, Loran OB, et al. Radical retropubic prostatectomy: the first russian experience of 15-year follow-up after surgery. Cancer Urology. 2013;9(2):57-62. (In Russ.). [Велиев Е.И., Петров С.Б., Лоран О.Б., и др. Радикальная простатэктомия: первый российский опыт 15-летнего наблюдения после операции. Онкоурология. 2013;9(2):57-62]. doi: 10.17650/1726-9776-2013-9-2-57-62
- Ludwig WW, Feng Z, Trock BJ, et al. Prostate Specific Antigen Testing after Radical Prostatectomy - Can We Stop at 20 Years? J Urol. 2018;199(1):114-119. doi: 10.1016/j.juro.2017.08.04
- Redondo C, Rozet F, Velilla G, et al. Complications of radical prostatectomy. Archivos Espanoles de Urologia. 2017;70(9):766-776.
- Venderbos LDF, Deschamps A, Dowling J, et al. Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients. European Urology Focus. 2021;7(5):987-994. doi: 10.1016/j.euf.2020.11.002
- Hamilton AS, Stanford JL, Gilliland FD, et al. Health outcomes after external-beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001;19(9):2517-2526. doi: 10.1200/JCO.2001.19.9.2517
- Chou R, LeFevre ML. Prostate cancer screening, the evidence, the recommendations and the clinical implications. JAMA. 2011;306(24):2721-2722. doi: 10.1001/jama.2011.1891
- Merriel S, Hetherington L, Seggie A, et al. Best practice in active surveillance for men with prostate cancer: A prostate cancer UK consensus statement. BJUI. 2019;124(1):47-54. doi: 10.1111/bju.14707
- Mahal BA, Butler S, Franco I, et al. Use of active surveillance or waiting for low-risk prostate cancer and management trends across risk groups in the United States 2010-2015. JAMA. 2019;321(7):704-706. doi: 10.1001/jama.2018.19941
- Albertsen PC. Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol. 2015;25(3):232-237. doi: 10.1097/MOU.0000000000000157
- Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomized population-based prostate- cancer screening trial. Lancet Oncol. 2010;11(8):725-732. doi: 10.1016/S1470-2045(10)70146-7
- Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868-878. doi: 10.1093/jnci/95.12.868
- Loeb S, Folkvaljon Y, Makarov DV, et al. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-238. doi: 10.1016/j.eururo.2014.06.010
- Polyakov SL, Shimanec SV, Karman AV, et al. Active surveillance in prostate cancer. Zdravoohranenie. 2020;9:58-67. (In Russ.). [Поляков С.Л., Шиманец С.В., Карман А.В., и др. Активное наблюдение при раке предстательной железы. Здравоохранение. 2020;9:58-67].
- Taratkin MS, Lauhtina EA, Adel'man KI, et al. Active surveillance in prostate cancer: to whom, when and how. Sechenov Medical Journal. 2019;10(3):37-44. (In Russ.). [Тараткин М.С., Лаухтина Е.А., Адельман К.И., и др. Активное наблюдение при раке простаты: кому, когда и как. Сеченовский вестник. 2019;10(3):37-44]. doi: 10.26442/22187332.2019.3.37-44
- Kokin SP, Nyushko KM, Alekseev BYa, Mailyan OA. Active surveillance in intermediate-risk prostate cancer. Experimental and Clinical Urology. 2022;15(3):55-63. (In Russ.). [Кокин С.П., Нюшко К.М., Алексеев Б.Я., Маилян О.А. Активное наблюдение при раке предстательной железы промежуточной группы риска. Экспериментальная и клиническая урология. 2022;15(3):55-63]. doi: 10.29188/2222-8543-2022-15-3-55-63
- Kinsella N, Helleman J, Bruinsma S, et al. Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018;7(1):83-97. doi: 10.21037/tau.2017.12.24
- Bokhorst LP, Valdagni R, Rannikko A, et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol. 2016;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007
- Matulewicz RS, Weiner AB, Schaeffer EM. Active surveillance for prostate cancer. JAMA. 2017;318(21):2152. doi: 10.1001/jama.2017.17222
- Bruinsma SM, Roobol MJ, Carroll PR, et al. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer – resultsof a modified Delphi consensus procedure. Nat Rev Urol. 2017;14(5):312-322. doi: 10.1038/nrurol.2017.26
- Liatsikos EN, Assimakopoulos K, Stolzenburg JU. Quality of life after radical prostatectomy. Urologia Internationalis. 2008;80(3):226-230. doi: 10.1159/000127331
- Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517-523. doi: 10.1097/01.ju.0000045749.90353.c7
- Gasanov EN, Chinenov DV, Akopyan GN, et al. The first results of active monitoring of patients with prostate cancer of low oncological risk. Andrology and Genital Surgery. 2021;22(2):78-83. (In Russ.). [Гасанов Э.Н., Чиненов Д.В., Акопян Г.Н., и др. Первые результаты активного наблюдения за больными раком предстательной железы низкого онкологического риска. Андрология и генитальная хирургия. 2021;22(2):78-83]. doi: 10.17650/1726-9784-2021-22-2-78-83
- Gasanov EN, Shpot' EV, Magomedov AA, et al. Low-risk prostate cancer: assessment of quality of life after surgical treatment and under active surveillance. Andrology and Genital Surgery. 2021;22(4):60-67. (In Russ.). [Гасанов Э.Н., Шпоть Е.В., Магомедов А.А., и др. Рак предстательной железы низкого онкологического риска: оценка качества жизни после хирургического лечения и при активном наблюдении. Андрология и генитальная хирургия. 2021;22(4):60-67]. doi: 10.17650/1726‐9784‐2021‐22‐4‐60‐67
- Andreeva RD, Nizamova RS. The state of oncological care for patients with prostate cancer in the Samara region, depending on age and treatment method. Aspirantskij vestnik Povolzh'ya. 2020;20(5-6):119-124. (In Russ.). [Андреева Р.Д., Низамова Р.С. Состояние онкологической помощи больным раком предстательной железы на территории Самарской области в зависимости от возраста и метода лечения. Аспирантский вестник Поволжья. 2020;20(5-6):119-124]. doi: 10.17816/2072-2354.2020.20.3.119-124
- Andreeva RD, Nizamova RS, Korabel'nikov AS, Zhurkina OV. The influence of the Gleason index on the survival of patients with localized prostate cancer in the Samara region. Vestnik medicinskogo instituta "Reaviz". 2022;(2):90-97. (In Russ.). [Андреева Р.Д., Низамова Р.С., Корабельников А.С., Журкина О.В. Влияние индекса Глисона на выживаемость больных локализованным раком предстательной железы в Самарской области. Вестник медицинского института «Реавиз». 2022;(2):90-97]. doi: 10.20340/vmi-rvz.2022.1.CLIN.2
- Andreeva RD. The effect of patient age on long-term outcomes of survival in prostate cancer. In: Aspirantskie chteniya – 2021. (In Russ.). [Андреева Р.Д. Влияние возраста пациентов на отдаленные результаты выживаемости при раке предстательной железы. В кн.: Аспирантские чтения – 2021]. Available et: https://elibrary.ru/item.asp?id=47959895 Accessed 01.02.2023.
Supplementary files
